Enrolment begins in the EBO-PEP trial in DRC

The Lancet Infectious Diseases · Published 2026-07-01 · DOI 10.1016/s1473-3099(26)00427-5

Authors (1)

Talha Burki

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Burki, T. (2026). Enrolment begins in the EBO-PEP trial in DRC. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(26)00427-5

Related articles

• The spread of sexually transmissible drug-resistant shigellosis in England: a genomic epidemiology study · The Lancet Infectious Diseases · 2026 · Same journal
• Updated Global Action Plan on Antimicrobial Resistance · The Lancet Infectious Diseases · 2026 · Same journal
• The wider value of RSV prevention · The Lancet Infectious Diseases · 2026 · Same journal
• Research in brief · The Lancet Infectious Diseases · 2026 · Same journal
• Genomic epidemiology of invasive meningococcal disease in Scotland before, during, and after the COVID-19 pandemic: a retrospective observational study · The Lancet Infectious Diseases · 2026 · Same journal
• New partnership to support TB vaccine implementation · The Lancet Infectious Diseases · 2026 · Same journal
• USA to end support of South Africa's HIV programmes · The Lancet Infectious Diseases · 2026 · Same journal
• Sabiha Essack—helping Africa lead the fight against AMR · The Lancet Infectious Diseases · 2026 · Same journal
• Indigenous Australians see surge in diphtheria cases · The Lancet Infectious Diseases · 2026 · Same journal
• A review of Bundibugyo virus and the 2026 outbreak: lessons for epidemic preparedness · The Lancet Infectious Diseases · 2026 · Same journal